Astria Therapeutics (ATXS) Net Income towards Common Stockholders: 2013-2018
Historic Net Income towards Common Stockholders for Astria Therapeutics (ATXS) over the last 6 years, with Dec 2018 value amounting to -$26.0 million.
- Astria Therapeutics' Net Income towards Common Stockholders fell 6.65% to -$5.9 million in Q4 2018 from the same period last year, while for Dec 2018 it was -$26.0 million, marking a year-over-year increase of 5.05%. This contributed to the annual value of -$26.0 million for FY2018, which is 4.93% up from last year.
- Latest data reveals that Astria Therapeutics reported Net Income towards Common Stockholders of -$26.0 million as of FY2018, which was up 4.93% from -$27.4 million recorded in FY2017.
- In the past 5 years, Astria Therapeutics' Net Income towards Common Stockholders registered a high of -$21.9 million during FY2014, and its lowest value of -$36.2 million during FY2016.
- Moreover, its 3-year median value for Net Income towards Common Stockholders was -$27.4 million (2017), whereas its average is -$29.9 million.
- In the last 5 years, Astria Therapeutics' Net Income towards Common Stockholders tumbled by 49.12% in 2015 and then grew by 24.22% in 2017.
- Astria Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$21.9 million in 2014, then plummeted by 49.12% to -$32.6 million in 2015, then fell by 10.77% to -$36.2 million in 2016, then climbed by 24.22% to -$27.4 million in 2017, then grew by 4.93% to -$26.0 million in 2018.